At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...

In vaccine development, the ability to tailor the body's immune response to a particular ... Different strategies for different outcomes The team started by mapping B cell lineages with single-cell ...

Financial Considerations Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and ...

In vaccine development, the ability to tailor the ... The team started by mapping B cell lineages with single-cell RNA sequencing, to determine whether various populations of B cells were, in ...

The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...

--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the appointment of ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.